ADPHC, AstraZeneca forge strategic partnership to enhance COPD awareness, care in Abu Dhabi
14 May 2025 00:05
ABU DHABI (WAM)The Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC (AstraZeneca) have signed a Memorandum of Understanding (MoU) to launch a collaborative public health project to strengthen public health initiatives, and improve outcomes for patients with chronic obstructive pulmonary disease (COPD) in Abu Dhabi emirate.
The MoU was signed on May 13 2025, by Dr. Omniyat Al Hajeri, Executive Director of Community Health sector, representing ADPHC, and Sameh El Fangary. Cluster President GCC, AstraZeneca, representing global biopharmaceutical AstraZeneca, during the 25th IUHPE World Conference on Health Promotion, taking place from May 13 to 16, 2025, at the Abu Dhabi National Exhibition Centre (ADNEC). Dr. Rashed Alsuwaidi, Director General of ADPHC said, "This partnership reflects our steadfast commitment to improving population health in Abu Dhabi through proactive and innovative approaches. By partnering with AstraZeneca, we aim to deliver comprehensive solutions that raise public awareness, promote early screening, and enable best-in-class care for COPD patients. This initiative builds upon the recommendations from the Abu Dhabi Public Health System Sustainability and Resilience (PHSSR) report and strengthens our vision of a healthier Abu Dhabi."Sameh El Fangary, Cluster President GCC, AstraZeneca shared, "Our most recent collaboration with ADPHC is a significant milestone in advancing public health and addressing the rising burden of chronic respiratory diseases in the UAE. Through this MoU, we are proud to support the UAE's healthcare priorities by sharing global best practices, driving education, and enabling early diagnosis and treatment pathways. Together, we are working towards a future where every patient has the opportunity to achieve better health outcomes and an improved quality of life."The strategic agreement outlines a shared vision between ADPHC and AstraZeneca to enhance population health through coordinated efforts centred around disease awareness, prevention, and best practice sharing. This shared vision will significantly benefit COPD patients in Abu Dhabi.The two-year partnership aligns with the company's mission to transform healthcare, and improve patient outcomes, through evidence-based and collaborative approaches.The strategic alliance focuses on three key pillars:-Disease Awareness: Jointly creating and executing public awareness campaigns to educate the community about COPD. This will include online and offline initiatives to encourage routine testing and early screening.-Disease Prevention: Developing early detection strategies to identify COPD in its initial stages, enabling timely intervention and management to reduce the long-term health burden on individuals and the healthcare system.-Best Practice Sharing: Utilising AstraZeneca's global insights and best practices in diagnostics and disease management to enhance patient care in Abu Dhabi. This may include workshops, knowledge exchange sessions with other AstraZeneca affiliates, and collaboration with international partners.A joint task force will be established, with ADPHC and AstraZeneca representatives to oversee the project's execution. The task force will be responsible for aligning strategic priorities, evaluating feasibility, and tracking the progress of each initiative under the Mou. All agreed-upon projects will be subject to further detailed documentation, and the implementation will proceed upon mutual approval from both parties' leadership.ADPHC, which is dedicated to elevating community health through innovation and integrated public health systems, continues to build on its commitment to address non-communicable diseases, including cancer and respiratory illnesses. As part of its broader public health strategy, ADPHC launched the Abu Dhabi Public Health Sustainability and Resilience (PHSSR) report, emphasising the need for early screening and legislative support to combat chronic diseases.AstraZeneca, a global leader in addressing non-communicable diseases (NCDs) in oncology, cardiovascular, renal, and metabolic diseases (CVRM), respiratory conditions such as COPD, and rare diseases, brings unparalleled expertise to the collaboration.
This partnership is a testament to the unwavering commitment of both ADPHC and AstraZeneca to improving public health in Abu Dhabi, and advancing innovative solutions for chronic disease management.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
2 days ago
- Gulf Today
elegant hoopoe Spotlights GCC Franchise Investment with Strategic Expansion
DUBAI, UAE – Esteemed weight loss and aesthetics clinic, elegant hoopoe, today announced a pivotal strategic move into franchising across the Gulf Cooperation Council (GCC), with a pronounced emphasis on the dynamic UAE market. This initiative is strategically designed to elevate the brand's social proof and capture heightened investor interest in its continued growth narrative. Mr. Shahriar Shahir Barzegar, the Founder and CEO of elegant hoopoe, has successfully guided the Dubai-based company to its current position of operational strength. With three flourishing branches already serving a discerning clientele, the brand has validated its business model and demonstrated significant market appeal for its specialized, high-end services. Further underscoring its expansionary vision, elegant hoopoe is advancing with plans for new clinic inaugurations in two key UAE locales: Abu Dhabi and Damac Hills. These developments are crucial components of the company's strategy to enhance the accessibility of its signature client experience, which harmoniously blends a welcoming ambiance with elegant and aspirational service delivery. "Our strategic entry into franchising is a transformative step for elegant hoopoe," remarked Mr. Shahriar Shahir Barzegar. "We have meticulously engineered a scalable and successful operational blueprint that consistently delivers superior client results within a sophisticated clinic setting. We are now inviting forward-thinking investors and partners who resonate with our vision to introduce elegant hoopoe's acclaimed services to a wider audience across the GCC. This is more than expansion; it's about cementing a leadership position as a credible and sought-after brand in the wellness and aesthetics landscape." The long-range strategy for elegant hoopoe is focused on achieving significant market presence and brand recognition throughout the GCC. Central to this is a franchise model developed to provide robust support to partners, offering a transparent and effective framework for operational success and investor value. elegant hoopoe is committed to empowering its franchisees with the comprehensive tools and in-depth knowledge necessary to consistently deliver its high service standards. This targeted franchising program is poised to attract investors and strategic allies eager to collaborate with a progressive brand dedicated to making meaningful contributions to personal wellbeing and aesthetic enhancement. elegant hoopoe remains firmly dedicated to principles of sustainable growth, unwavering brand integrity, and the delivery of exceptional value to its clients and franchise network. About elegant hoopoe: elegant hoopoe is a leading clinic in weight loss and aesthetics, headquartered in Dubai, UAE. Founded by Mr. Shahriar Shahir Barzegar, the clinic offers a curated selection of specialized services, enabling clients to achieve their wellness and aesthetic goals within a uniquely welcoming, elegant, and aspirational setting. With a steadfast commitment to innovation and client-centric care, elegant hoopoe is strategically positioned for significant growth and market leadership across the GCC. Discover more at .
Zawya
3 days ago
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
Al Etihad
3 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
